| |
Audit
|
Nominating and Governance
|
Compensation
|
Communications
|
James F. Gero
|
|
|
|
|
Chairman of the Board of Directors, Director of Intrusion, Inc., Drew Industries, Inc. and Greenleaf, Inc. Mr. Gero became Chairman of Orthofix International N.V. on Jan. 1, 2005, and has been a Director of Orthofix International N.V. since 1998. Mr. Gero became a Director of AME Inc. in 1990. He is a Director of Intrusion, Inc. and Drew Industries Inc. as well as being a private investor.
Holdings: 102,504 shares
View Transactions
|
| Date |
Type |
Shares Traded |
Price Range |
| May 8, 2008 |
Buy |
4,500 |
37.90 |
| May 7, 2008 |
Buy |
3,000 |
37.24 |
| May 6, 2008 |
Buy |
7,500 |
36.17 |
| May 11, 2007 |
Buy |
10,000 |
47.28 - 47.35 |
| Aug 25, 2006 |
Buy |
8,676 |
39.50 - 39.69 |
| Aug 18, 2006 |
Buy |
15,224 |
38.78 |
| Aug 17, 2006 |
Buy |
1,100 |
38.81 |
|
Charles W. Federico
|
|
|
|
|
Director Mr. Federico became a Director of Orthofix International N.V. in October 1996 and was the President of Orthofix Inc. from October 1996 to Jan. 1, 2002. On Jan. 1, 2001, Mr. Federico was appointed President and Chief Executive Officer of Orthofix International N.V. From 1985 to 1996, Mr. Federico was the President of Smith & Nephew Endoscopy (formerly Dyonics, Inc.). From 1981 to 1985, Mr. Federico served as Vice President of Dyonics, initially as Director of Marketing and subsequently as General Manager. Previously, he held management and marketing positions with General Foods Corporation, Air Products Corporation, Puritan Bennett Corporation and LSE Corporation. Effective April 1, 2006, Mr. Federico resigned as President and Chief Executive Officer of Orthofix International N.V. but remains on the Board of Directors.
Holdings: 4,325 shares
View Transactions
|
| Date |
Type |
Shares Traded |
Price Range |
| Dec 5, 2006 |
Sell |
43,800 |
45.00 - 45.20 |
| Dec 5, 2006 |
Option Execute |
43,800 |
37.76 - 43.04 |
| Aug 31, 2006 |
Sell |
124,900 |
39.15 - 39.74 |
| Aug 31, 2006 |
Option Execute |
124,900 |
17.88 - 37.76 |
| Aug 30, 2006 |
Sell |
125,100 |
39.76 - 39.90 |
| Aug 30, 2006 |
Option Execute |
125,100 |
17.88 |
|
Alan W. Milinazzo
|
|
|
|
|
Director, Group President and CEO Mr. Milinazzo joined Orthofix International in 2005 as Chief Operating Officer and succeeded to the position of CEO the following year. Prior to joining Orthofix, Mr. Milinazzo was Vice President of Medtronic Inc.'s Vascular business, as well as, Vice President and General Manager of Medtronic's Coronary and Peripheral businesses. Prior to his time with Medtronic, Mr. Milinazzo spent 12 years as an executive with Boston Scientific Corporation in numerous roles, including Vice President of Marketing for SCIMED Europe. Mr. Milinazzo brings more than two and a half decades of experience in the management and marketing of medical device businesses, including positions with Aspect Medical Systems and American Hospital Supply. He earned a bachelor's degree, cum laude, at Boston College in 1981.
|
Peter J. Hewett
|
|
|
|
|
Director Mr. Hewett was appointed Deputy Chairman of the Board of Directors in 2005 and has been a non-executive Director of Orthofix International N.V. since March 1992. He was the Deputy Group Chairman of Orthofix International N.V. between March 1998 and December 2000. Previously, Mr. Hewett served as the Managing Director of Caradon Plc, Chairman of the Engineering Division, Chairman and President of Caradon Inc., Caradon Plc's U.S. subsidiary and a member of the Board of Directors of Caradon Plc of England. In addition, he was responsible for Caradon Plc's worldwide human resources function and the development of its acquisition opportunities.
Holdings: 59,800 shares
View Transactions
|
| Date |
Type |
Shares Traded |
Price Range |
| Nov 5, 2007 |
Automatic Sell |
2,875 |
52.04 - 52.51 |
| Nov 5, 2007 |
Option Execute |
5,275 |
10.63 |
| Oct 29, 2007 |
Automatic Sell |
5,750 |
53.02 - 53.40 |
| Oct 29, 2007 |
Option Execute |
10,550 |
10.63 |
| Oct 22, 2007 |
Automatic Sell |
5,750 |
51.45 - 51.70 |
| Oct 22, 2007 |
Option Execute |
10,550 |
10.63 |
| Oct 15, 2007 |
Automatic Sell |
5,750 |
50.15 - 50.95 |
| Oct 15, 2007 |
Option Execute |
10,550 |
10.63 |
| Oct 8, 2007 |
Automatic Sell |
5,750 |
49.72 - 50.01 |
| Oct 8, 2007 |
Option Execute |
10,550 |
10.63 |
| Oct 1, 2007 |
Automatic Sell |
2,875 |
47.91 - 49.45 |
| Oct 1, 2007 |
Option Execute |
5,275 |
10.63 |
| Sep 24, 2007 |
Automatic Sell |
2,875 |
46.58 - 47.20 |
| Sep 24, 2007 |
Option Execute |
5,275 |
10.63 |
| Sep 17, 2007 |
Automatic Sell |
2,875 |
45.47 - 45.51 |
| Sep 17, 2007 |
Option Execute |
2,875 |
10.63 |
|
Jerry C. Benjamin
|
|
|
|
|
General Partner, Advent Ltd. Mr. Benjamin became a non-executive Director of Orthofix International N.V. in March 1992. He has been a General Partner of Advent Venture Partners, a venture capital management firm in London since 1985. In the past, Mr. Benjamin was a Director for a number of private healthcare companies.
|
Walter P. von Wartburg
|
|
|
|
|
Chairman of the Board of Directors, Attorney-at-law and Partner, Law & Life Sciences Consultancy, Switzerland Dr. von Wartburg became a non-executive Director of Orthofix International N.V. in June 2004. He is an attorney and has practiced privately in his own law firm in Basel, Switzerland since 1999, specializing in life sciences law. He has also been a professor of administrative law and public health policy at the Saint Gall Graduate School of Economics in Switzerland for 25 years. Previously, he held top management positions with Ciba Pharmaceuticals and Novartis at their headquarters in Basel, Switzerland. In addition, Mr. von Wartburg currently serves as a Director on the board of Nymox Pharmaceutical Corporation.
|
Thomas J. Kester CPA
|
|
|
|
|
Retired KPMG LLP audit partner Mr. Kester became a non-executive Director of Orthofix International N.V. in August 2004. Mr. Kester retired after 28 years, 18 as an audit partner, from KPMG LLP in 2002. While at KPMG, he served as the lead audit engagement partner for both public and private companies and also served four years on KPMG's National Continuous Improvement Committee. Mr. Kester earned a bachelor of science degree in mechanical engineering from Cornell University and an MBA degree from Harvard University.
Holdings: 4,000 shares
View Transactions
|
| Date |
Type |
Shares Traded |
Price Range |
| May 9, 2008 |
Buy |
2,000 |
33.01 - 33.19 |
| May 14, 2007 |
Buy |
1,000 |
47.34 |
|
Guy Jordan PhD
|
|
|
|
|
Director Dr. Jordan became a non-executive Director of Orthofix International N.V. in December 2004. Most recently, Dr. Jordan served as a group president at CR Bard, Inc., a medical device company, where he had strategic and operating responsibilities for Bard's global oncology business and functional responsibility for all of Bard's research and development. Dr. Jordan earned a Ph.D. in organic chemistry from Georgetown University as well as an MBA from Fairleigh Dickinson University. He also currently serves on the boards of Specialized Health Products International, Inc., Xillix Technologies Corporation and EsophyX, Inc.
|
Kenneth R. Weisshaar
|
|
|
|
|
Director Mr. Weisshaar became a non-executive Director of Orthofix International N.V. in December 2004. Most recently, Mr. Weisshaar has served as Chief Operating Officer and strategy advisor for Sensatex, Inc. Also, Mr. Weisshaar spent 12 years as a corporate officer at Becton Dickson, a medical device company, where at different times he was responsible for global businesses in medical devices and diagnostic products and served as Chief Financial Officer and Vice President, Strategic Planning. Mr. Weisshaar earned a bachelor of science degree from MIT and an MBA from Harvard University. He currently also serves on the board of Digene Corporation.
|
Stock transaction information provided by EDGAR Online. Orthofix International N.V. makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.